Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 9Other hematologic neoplasm 4Breast 4Gynecologic 2Genitourinary 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1Classical hematology 1

Conditions

Solid Tumor Refractory to Standard Therapy 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Sodium Chloride × Other solid neoplasm × Clear all
NCT04026321 2019-07-19

Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US

Livzon Pharmaceutical Group Inc.

Phase 1 Completed
40 enrolled
Other solid neoplasm

Solid Tumor Refractory to Standard Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡